Earnings Summary: Highlights of Boston Scientific’s Q3 2025 results

Medical device maker Boston Scientific Corporation (NYSE: BSX) on Wednesday reported financial results for the third quarter of 2025. The company also issued guidance for Q4 and fiscal 2025.

• The company reported net sales of $5.065 billion for Q3, an increase of 20.3% from the year-ago quarter
• Q3 sales grew 19.4% year-over-year on an operational basis; and 15.3% on an organic basis
• Net income attributable to stockholders was $0.51 per share in Q3, vs. $0.32 per share in the year-ago quarter
• Adjusted earnings per share rose to $0.75 from $0.63 per share in the comparable quarter of FY24
• For the fourth quarter of FY25, the company estimates net sales growth in the range of 14.5% to 16.5%
• On an organic basis, Q4 sales are expected to grow between 11% and 13%
• The guidance for unadjusted Q4 EPS is $0.48-$0.52, and the adjusted EPS outlook is $0.77-$0.79
• For fiscal 2025, the company expects net sales growth to be around 20%, on a reported basis
• It is looking for full-year earnings of $1.97-2.01 per share on a reported basis, and $3.02-3.04 per share on an adjusted basis